Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The launch of a groundbreaking clinical trial in oncology and the publication of guidance from the US FDA highlight increasing support for the use of adaptive clinical trials in the development of new drugs.
This article explores some of the challenges and opportunities in developing personalized treatment for patients with cancer, which could improve outcomes, reduce toxicity, improve efficiency in drug development and help control the rising costs of cancer care.
Recent advances in stem cell technology are allowing the production of a variety of human cell types that could provide the basis for more effective drug screening for toxicity and efficacy, as well as more relevant disease modelling based on induced pluripotent stem cells derived from patients.
In this Review, the authors discuss recent advances in the characterization of β-arrestin-mediated signalling and biased agonism at seven-transmembrane receptors, and address the implications of these for drug discovery involving this ubiquitous superfamily of receptors.
Alzheimer's disease (AD) presents the largest unmet need in neurology. This article provides an overview of the rationale and the issues that underlie the different strategies for drug discovery in AD, with a focus on approaches aimed at slowing or halting disease progression.
Ca2+ release-activated Ca2+(CRAC) channels are involved in a vast array of cellular responses, and abnormal channel activity has now been linked to many diseases including immunodeficiency and autoimmunity disorders, allergy, and cancer. Here, Parekh discusses recent advances in understanding the molecular basis, gating and function of CRAC channels, as well as the therapeutic potential of CRAC channel inhibitors.
